Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact firstname.lastname@example.org.
Construction and Comprehensive Analysis of a Competitive Endogenous RNA Network and Potential Regulatory Axes in Gastric Cancer
22 Pages Posted: 12 Apr 2019More...
Background: Long non-coding RNAs (lncRNAs) have been identified as micro RNA (miRNA) sponges in a competing endogenous RNA (ceRNA) network, and are involved in the regulation of gene expression. This study aims to construct a lncRNA-associated ceRNA network in GC.
Methods: Differentially expressed lncRNAs, mRNAs, and miRNAs were identified by analyzing the expression profiles of GC retrieved from The Cancer Genome Atlas (TCGA) database. The lncRNA-miRNA-mRNA regulatory networks of GC were constructed by comprehensive bioinformatics methods including functional annotation, RNA-RNA interactomes prediction, correlation analysis, and survival analysis. The interactions and correlations among ceRNAs were validated by experiments on cancer tissues and cell lines.
Results: A total of 41 lncRNAs, 9 miRNAs, and 10 mRNAs were identified and selected to establish the ceRNA regulatory network of GC. Several ceRNA regulatory axes, which consist of 18 lncRNAs, 4 miRNAs, and 6 mRNAs, were obtained from the network. A potential ADAMTS9-AS2/miR-372/CADM2 axis which perfectly conformed to the ceRNA theory was further analyzed. qRT-PCR revealed that ADAMTS9-AS2 knockdown significantly increased miR-372 expression but reduced CADM2 expression, while ADAMTS9-AS2 overexpression had the opposite effects. Dual luciferase reporter assay indicated that miR-372 could bound to the ADAMTS9-AS2 and the 3'UTR of CADM2.
Conclusions: The constructed novel ceRNA network and the potential regulatory axes might provide a comprehensive understanding of the potential mechanisms of development in GC. The ADAMTS9-AS2/miR-372/CADM2 axis could serve as a potential therapeutic target for GC treatment.
Funding Statement: This study was supported by Beijing Natural Science Foundation (7184240).
Declaration of Interests: The authors declare: "None."
Ethics Approval Statement: Written informed consent was obtained from all patients. This study was performed with the approval of the Ethics Committee of the Beijing Hospital.
Keywords: Gastric cancer; Competing endogenous RNA; Bioinformatics analysis; Prognostic biomarker; Experimental validation
Suggested Citation: Suggested Citation